??? ?????? ?? ??? ?? ??????? ??????? ??? ??????? ??? ??????:Individuals who experienced an incomplete antileukemic reaction obtained a 2nd induction program where mitoxantrone or daunorubicin was administered for two days and cytarabine for 5 times using the very same everyday dosage routine. Response rates and median survival information and facts… Read More

MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers… Read More